High Risk on Clinical Product: The company places all its eggs in one basket with its clinical product, which may not ultimately work. This single-product focus increases uncertainty and potential instability. Additionally, there is a tunnel vision approach, which limits exploration of other potentially viable opportunities.
Job Security Concerns: As a start-up/scale-up company, bit.bio faces yearly risks related to job security. There are recurring issues with securing funding, and the company does not invest or put enough focus on revenue generation despite having a good product.
Clear Financial Mismanagement
Deteriorating Culture: The company culture has significantly declined. While culture was a priority at first, bit.bio now harbors a toxic environment where politics permeate all areas. There is a notable lack of compassion and respect for staff.
Limited Career Progression: Career progression opportunities are limited. HR's use of vague, benchmarked frameworks for career advancement creates a sense of gaslighting among the team, as these frameworks are not specific to job roles.